Validation of the Framingham general cardiovascular risk score in a multiethnic Asian population: a retrospective cohort study.
Yook Chin Chia, Sarah Yu Weng Gray, Siew Mooi Ching...
https://pubmed.ncbi.nlm.nih.gov/25991451/Actively Recruiting
Led by Watcharasak Chotiyaputta · Updated on 2026-10-08
251
Participants Needed
1
Research Sites
474 weeks
Total Duration
Metabolic dysfunction-associated steatotic liver disease MASLD is common in Thailand and strongly linked to metabolic issues such as obesity, diabetes, high blood pressure, and abnormal cholesterol levels. Cardiovascular disease CVD is the leading cause of death among those with MASLD. This study investigates how well cardiovascular risk tools relate to coronary artery calcium CAC scores in Thai MASLD patients to better assess heart risk in this group. The study observes Thai adult patients diagnosed with MASLD who have undergone CAC scoring using non-contrast cardiac CT. Clinical, metabolic, liver disease severity, and CAC score data are collected to examine associations between cardiovascular risk calculatorssuch as the Thai CV Risk Scoreand coronary calcification. This study does not involve treatment but gathers data to improve risk prediction. Participants provide clinical and laboratory data needed for cardiovascular risk assessment along with liver fibrosis scores. Researchers analyze these data alongside CAC scores to see how well existing risk tools correlate with coronary artery calcification. The primary measurement is the association between the Thai CV Risk Score and CAC score at baseline. The study runs from June 2026 through June 2036, with ongoing data collection and monitoring throughout this period.
CONDITIONS
Cardiovascular Risk Assessment and Coronary Calcium Score in Thai MASLD Patients
A
Assoc. Prof. Watcharasak Chotiyaputta, M.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Watcharasak Chotiyaputta
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 10 years
Participants who have been diagnosed with MASLD and undergone coronary artery calcium scoring provide clinical, laboratory, and liver fibrosis data. This information is collected to evaluate cardiovascular risk assessment tools and their association with coronary calcification.
Periodic data collection visits as per study schedule
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Yook Chin Chia, Sarah Yu Weng Gray, Siew Mooi Ching...
https://pubmed.ncbi.nlm.nih.gov/25991451/Yong-Jae Lee, Jae-Yong Shim, Byung-Soo Moon...
https://pubmed.ncbi.nlm.nih.gov/21750929/Ralph B D'Agostino, Ramachandran S Vasan, Michael J Pencina...
https://pubmed.ncbi.nlm.nih.gov/18212285/Ovidio De Filippo, Gianluca Di Pietro, Marco Nebiolo...
https://pubmed.ncbi.nlm.nih.gov/38396359/Abhinav Sharma, Neha J Pagidipati, Robert M Califf...
https://pubmed.ncbi.nlm.nih.gov/31992065/Tracey G Simon, Bjorn Roelstraete, Hannes Hagström...
https://pubmed.ncbi.nlm.nih.gov/34489307/Donna K Arnett, Roger S Blumenthal, Michelle A Albert...
https://pubmed.ncbi.nlm.nih.gov/30879339/Eleni Michalopoulou, John Thymis, Stamatios Lampsas...
https://pubmed.ncbi.nlm.nih.gov/39860434/Teresa J H Christianson, Sandra C Bryant, Audrey J Weymiller...
https://pubmed.ncbi.nlm.nih.gov/16706261/Gabrielle S Gershon, Jaret R Barr, Alexander C Razavi...
https://pubmed.ncbi.nlm.nih.gov/41078705/Watcharasak Chotiyaputta
Lead Sponsor